Lamotrigine Extended-Release In Elderly Patients With Epilepsy
Public ClinicalTrials.gov record NCT00516139. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Lamotrigine Extended-Release in Elderly Patients With Epilepsy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing.
Study identification
- NCT ID
- NCT00516139
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 122 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 65 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2007
- Primary completion
- Jun 30, 2010
- Completion
- Jun 30, 2010
- Last update posted
- Jan 17, 2017
2007 – 2010
United States locations
- U.S. sites
- 63
- U.S. states
- 28
- U.S. cities
- 57
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35294-0021 | — |
| GSK Investigational Site | Gilbert | Arizona | 85234 | — |
| GSK Investigational Site | Litchfield Park | Arizona | 85340 | — |
| GSK Investigational Site | Phoenix | Arizona | 85003 | — |
| GSK Investigational Site | Phoenix | Arizona | 85013 | — |
| GSK Investigational Site | Fresno | California | 93710 | — |
| GSK Investigational Site | Fullteron | California | 92835 | — |
| GSK Investigational Site | Irvine | California | 92618 | — |
| GSK Investigational Site | Los Angeles | California | 90073 | — |
| GSK Investigational Site | Pasadena | California | 91106 | — |
| GSK Investigational Site | Fort Collins | Colorado | 80524 | — |
| GSK Investigational Site | Newark | Delaware | 19713 | — |
| GSK Investigational Site | Gainesville | Florida | 32610 | — |
| GSK Investigational Site | Jacksonville | Florida | 32224 | — |
| GSK Investigational Site | Jacksonville | Florida | 32266 | — |
| GSK Investigational Site | Melbourne | Florida | 32901 | — |
| GSK Investigational Site | Miami | Florida | 33136 | — |
| GSK Investigational Site | Ponte Vedra Beach | Florida | 32082 | — |
| GSK Investigational Site | Sarasota | Florida | 34233 | — |
| GSK Investigational Site | Atlanta | Georgia | 30309 | — |
| GSK Investigational Site | Atlanta | Georgia | 30322 | — |
| GSK Investigational Site | Suwanee | Georgia | 30024 | — |
| GSK Investigational Site | Boise | Idaho | 83702 | — |
| GSK Investigational Site | Springfield | Illinois | 62702 | — |
| GSK Investigational Site | Fort Wayne | Indiana | 46805 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46256 | — |
| GSK Investigational Site | Wichita | Kansas | 67214 | — |
| GSK Investigational Site | Louisville | Kentucky | 40202 | — |
| GSK Investigational Site | Scarborough | Maine | 4074 | — |
| GSK Investigational Site | Burlington | Massachusetts | 01805 | — |
| GSK Investigational Site | Hopedale | Massachusetts | 01747 | — |
| GSK Investigational Site | Traverse City | Michigan | 49684 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55422 | — |
| GSK Investigational Site | Saint Paul | Minnesota | 55102 | — |
| GSK Investigational Site | Chesterfield | Missouri | 63017 | — |
| GSK Investigational Site | Kansas City | Missouri | 64111 | — |
| GSK Investigational Site | Henderson | Nevada | 89014 | — |
| GSK Investigational Site | Camden | New Jersey | 08103 | — |
| GSK Investigational Site | Newark | New Jersey | 07103 | — |
| GSK Investigational Site | Summit | New Jersey | 07901 | — |
| GSK Investigational Site | Cedarhurst | New York | 11516 | — |
| GSK Investigational Site | Rochester | New York | 14642 | — |
| GSK Investigational Site | Schenectady | New York | 12308 | — |
| GSK Investigational Site | Columbus | Ohio | 43210 | — |
| GSK Investigational Site | Toledo | Ohio | 43614 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19102 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15240 | — |
| GSK Investigational Site | Sellersville | Pennsylvania | 18960 | — |
| GSK Investigational Site | Columbia | Tennessee | 38401 | — |
| GSK Investigational Site | Cordova | Tennessee | 38018 | — |
| GSK Investigational Site | Germantown | Tennessee | 38139 | — |
| GSK Investigational Site | Nashville | Tennessee | 37232 | — |
| GSK Investigational Site | Dallas | Texas | 75214 | — |
| GSK Investigational Site | Dallas | Texas | 75230 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | Temple | Texas | 76508 | — |
| GSK Investigational Site | Richmond | Virginia | 23298 | — |
| GSK Investigational Site | Bremerton | Washington | 98310 | — |
| GSK Investigational Site | Madison | Wisconsin | 53715 | — |
| GSK Investigational Site | Milwaukee | Wisconsin | 53215 | — |
| GSK Investigational Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00516139, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 17, 2017 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00516139 live on ClinicalTrials.gov.